I would frame this as building physical activity as a core health behavior rather than focusing on exercise solely for weight maintenance
With its potential to boost energy expenditure and improve insulin sensitivity, this peptide can support overall metabolic health
If you experience these, Cho says to report them to your doctor
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
There were 60,000 fewer hospitalizations and heart attacks and 22,000 fewer hospitalizations for strokes, says Dr
Klin Monatsbl Augenheilkd 63:678683 Gorlin RJ, Anderson RC, Blaw ME (1969) Multiple lentigines syndrome: complex comprising multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities of genitalia, retardation of growth, sensorineural deafness, and autosomal dominant hereditary pattern
